Adult Immunization | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

142

June 1, 2014

View Complete Issue Table of Contents 2019

Adult Immunization

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Adult Immunization

June 1, 2014 (Issue: 142)

Superseded by The Medical Letter "Adult Immunization" - Issue 1661, October 17, 2022

Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in...more

Show References Hide References

1. Advice for travelers. Treat Guidel Med Lett 2012; 10:45.

2. CB Bridges et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:110.

3. Influenza vaccine for 2013-2014. Med Lett Drugs Ther 2013; 55:73.

4. CS Ambrose et al. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011; 5:67.

5. AR Falsey et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172.

6. RK Zimmerman et al. Randomized clinical trial of high-dose influenza vaccine in nursing home residents. Presented at IDWeek, San Francisco, CA, October 2-6, 2013. Abs. 576b. Available at: https://idsa.confex.com. Accessed May 12, 2014.

7. DP Greenberg. Fluzone high-dose vaccine efficacy trial results. Presented at ACIP meeting, Oct 24, 2013. Available at: www.cdc.gov. Accessed May 12, 2014.

8. SB Omer et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011; 8:e1000441.

9. K Zaman et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555.

10. AA Eick et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011; 165:104.

11. Centers for Disease Control and Prevention (CDC). Notice to readers: final 2012 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2013; 62:669.

12. Adacel and Boostrix: Tdap vaccines for adolescents and adults. Med Lett Drugs Ther 2006; 48:5.

13. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131.

14. Cervarix - a second HPV vaccine. Med Lett Drugs Ther 2010; 52:37.

15. A human papillomavirus vaccine. Med Lett Drugs Ther 2006; 48:65.

16. HPV vaccine for boys? Med Lett Drugs Ther 2011; 53:20.

17. E Herweijer et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311:597.

18. JM Palefsky et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.

19. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males – Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705.

20. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915.

21. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48:73.

22. Herpes zoster vaccine (Zostavax) revisited. Med Lett Drugs Ther 2010; 52:41.

23. KE Schmader et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922.

24. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011; 60:1528.

25. KE Schmader et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320.

26. Centers for Disease Control and Prevention (CDC). Measles – United States, January 1-August 24, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:741.

27. HQ McLean et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-4):1.

28. AP Fiebelkorn et al. Manual for the surveillance of vaccine-preventable diseases. 5th edition, CDC, 2013, chapter 9. Available at www.cdc.gov. Accessed May 12, 2014.

29. Institute of Medicine. Adverse effects of vaccines: evidence and causality. Consensus report August 25, 2011. Available at www.iom. edu. Accessed March 14, 2014.

30. Centers for Disease Control and Prevention (CDC) and Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102.

31. S Moberley et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422.

32. A Huss et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48.

33. Pneumococcal vaccine for adults. Med Lett Drugs Ther 2012; 54:87.

34. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816.

35. CAPiTA Study findings presented at 9th international symposium on pneumococci and pneumococcal diseases (ISPPD), Hyderabad, India, March 12, 2014. Pfizer Press Release. Available at www.pfizer.com. Accessed May 12, 2014.

36. EA Clutterbuck et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408.

37. CDC. Epidemiology and prevention of vaccine-preventable diseases. The Pink Book, 12th edition, May 2012, chapter 8: hepatitis A. Available at: www.cdc.gov. Accessed May 14, 2014.

38. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1709.

39. A new conjugate meningococcal vaccine (Menveo). Med Lett Drugs Ther 2010; 52:59.

40. KS Reisinger et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16:1810.

41. AC Cohn et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1.

42. CDC. Epidemiology and prevention of vaccine-preventable diseases. The Pink Book, 12th edition, May 2012, chapter 13: meningococcal disease. Available at: www.cdc.gov. Accessed May 14, 2014.

43. Prevention of meningococcal B disease. Med Lett Drugs Ther 2013; 55:97.

44. NJ Carter. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero): a review of its use in primary and booster vaccination. BioDrugs 2013; 27:263.

45. EC Briere et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-1):1.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.